A case report of Trousseau syndrome

Medicine (Baltimore). 2023 Jul 28;102(30):e34449. doi: 10.1097/MD.0000000000034449.

Abstract

Rationale: In 1865, Trousseau first discovered pulmonary embolism caused by multiple venous thrombosis in patients with gastric cancer, and later all clinical manifestations of malignant patients during pathogenesis due to abnormal coagulation and fibrinolysis were referred to collectively as Trousseau syndrome. Trousseau syndrome is not a benign thrombophlebitis, and when diagnosed it requires immediate treatment. The survival rate over 1 year is only 12%. Stroke in cancer patients has distinct characteristics different from conventional stroke and has higher mortality.

Patient concerns: A 54-year-old female presented to the Department of Otolaryngology with recurrent right nasal bleeding for 4 days. After surgery, the patient experienced 7 different cerebral infarction courses. Finally died of brain herniation.

Diagnosis: The specific abnormal laboratory index is the increase of D-dimer, suggesting the hypercoagulation state. The patient developed multiple cerebral infarction, myocardial injury, renal infarction, splenic infarction, and lower extremity arterial thrombosis, and finally was diagnosed Trousseau syndrome.

Interventions: In the treatment, aspirin and atorvastatin were selected, but it did not work very well. D-dimer were high, we used low molecular weight heparin, and D-dimer decreased significantly.

Outcomes: Finally the patient died of brain herniation.

Conclusion: The raise of D-dimer and typical magnetic resonance imaging manifestation which provides a greater basis for diagnosis. The specific abnormal laboratory index is the increase of D-dimer, which provides direction for treatment and helps to evaluate treatment effect.

Publication types

  • Case Reports

MeSH terms

  • Cerebral Infarction / drug therapy
  • Cerebral Infarction / etiology
  • Female
  • Heparin, Low-Molecular-Weight / therapeutic use
  • Humans
  • Middle Aged
  • Stroke* / drug therapy
  • Syndrome
  • Thrombosis* / drug therapy

Substances

  • Heparin, Low-Molecular-Weight